Minghao Zheng is Professor of Orthopaedic Research at the University of Western Australia, and heads the Bone-Brain Axis research division at the Perron Institute for Translational and Neurological Science in Perth. After studying medicine at Shantou University and Sun Yat-sen University of Medical Sciences in China, Professor Zheng received a PhD (1993) and Doctor of Medicine (2000) from UWA.
Professor Zheng is an expert in the field of regenerative medicine, in particular the translation of novel science into clinical practice, including the regeneration of tendon and cartilage using a patient’s own stem cells. He developed Matrix-induced Autologous Implantation (MACI) for cartilage repair of the adult knee; Autologous Tenocyte Implantation therapy (Ortho-ATI™) for chronic tendon injuries; and CelGro™ collagen scaffold for cartilage, tendon, ligament and nerve cell repair and dental applications, which has gained FDA, TGA and CE Mark approval.
Professor Zheng is co-founder of Orthocell Limited (ASX:OCC), a company established to commercialise orthopaedic innovations; co-founder and scientific consultant at Captix Biomedical, a biotech company creating innovative technologies to deliver cell therapies; and established Marine Biomedical Pty Ltd to develop PearlBoneTM from pearl nacre into a synthetic bone substitute for the orthopaedic device sector.
He has authored more than 250 scientific publications with over 9,500 citations and H index of 54, and holds 11 patent families in orthopaedics and cellular therapy worldwide. He is fellow of the Royal College of Pathologists, UK, the Royal College of Pathologists of Australasia, and the Royal Society of Medicine; and is associate editor of Stem Cell Research & Therapy and J Orthopaedic Translation, is an editorial board member of Int. J Biological Sci, and a member of Faculty Opinions.